市場調查報告書
商品編碼
1347972
全球宮腔鏡市場 - 2023-2030Global Hysteroscopy Market - 2023-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
宮腔鏡檢查主要用於識別和治療引起異常子宮出血、月經過多、經期間不規則滴血以及絕經後出血的疾病。該手術允許外科醫生使用一種稱為宮腔鏡的工具觀察子宮內部。它通常在醫院或門診手術中心進行,通常在全身麻醉或脊髓麻醉下進行。
宮腔鏡檢查可以是診斷過程以及治療過程的一部分。診斷性宮腔鏡檢查可識別子宮結構異常,也可用於確認超音波等其他檢查的結果。手術宮腔鏡檢查治療診斷性宮腔鏡檢查期間發現的異常,子宮內膜去除術是治療異常子宮出血的常見手術。
此外,技術進步、產品推出和投資增加等重要的成長動力將推動未來市場的成長。 Medtronic Plc.、Olympus Corporation、B. Braun Melsungen AG、Stryker Corporation、Hologic Inc. 等重要參與者都在市場上積極營運。
宮腔鏡檢查是使用宮腔鏡進行的,宮腔鏡是一根細長的發光管,插入陰道以檢查子宮頸和子宮內部。大公司推出的產品有助於推動市場成長,這些有效的研發有助於新診斷和治療的產品推出,以改善數百萬婦科疾病患者的護理。
例如,2023 年 7 月,GenWorks Health 推出了機械宮腔鏡組織切除系統,該系統使用簡單的機械方法去除宮內組織。它是一種微創系統,已被證明速度更快,還可以完全切除子宮內膜肌瘤和息肉。
此外,UroViu 公司於 2022 年 6 月推出了新型 Hystero-V,這是一款與 UroViu 的 Always Ready 內視鏡平台兼容的拋棄式宮腔鏡。 12-Fr、半剛性 Hystero-V 具有親水塗層,可實現輕柔插入和卓越的可視化,從而實現高效的宮內檢查。因此,由於上述因素,預計市場在預測期內將會提振。
宮腔鏡檢查是一種微創干涉措施,可用於診斷和治療許多子宮內和宮頸內膜問題。主要公司的主要投資有助於推動市場成長,而來自國家組織和公司的這些有效資金有助於將研究發現轉化為婦科疾病的新診斷和治療方法。
例如,2020 年 10 月,Meditrina 籌集了 1300 萬美元,用於將用於治療宮內病變的 Aveta 系統商業化。 Aveta 系統設計為使用專有的可擴展工作通道宮腔鏡以及液體管理和切除系統,在連續流動條件下進行宮腔鏡組織碎片切除
與宮腔鏡檢查相關的缺點包括宮腔鏡檢查設備和手術的成本高昂、發展中國家缺乏訓練有素的專業人員、與手術相關的併發症和感染的風險、某些地區缺乏對微創手術的認知和不願意、對批准微創手術的嚴格規定。宮腔鏡設備和農村地區先進醫療設施的使用機會有限。例如,在美國,宮腔鏡檢查的總費用在 2800 美元到 4800 美元之間。因此,這些因素限制了市場的成長。
Hysteroscopy is primarily used to identify and treat conditions that cause abnormal uterine bleeding, heavy menstrual bleeding, irregular spotting between periods, and bleeding after menopause. The procedure allows the surgeon to look inside of uterus with a tool called a hysteroscope. It is typically performed in a hospital or outpatient surgical center and is usually done under general or spinal anesthesia.
Hysteroscopy can be a part of the diagnostic process, as well as the treatment process. Diagnostic hysteroscopy identifies structural irregularities in the uterus and also can be used to confirm the results of other tests such as an ultrasound. Operative hysteroscopy treats an abnormality detected during a diagnostic hysteroscopy and endometrial ablation is a common procedure that treats abnormal uterine bleeding.
Furthermore, significant growth drivers such as increasing technological advancements, product launches, and rising investments give rise to future market growth. Significant key players like Medtronic Plc., Olympus Corporation, B. Braun Melsungen AG, Stryker Corporation, Hologic Inc., and others are actively operating in the market.
Hysteroscopy is done using a hysteroscope which is a thin, lighted tube that is inserted into the vagina to examine the cervix and inside of the uterus. The product launches by major companies help to drive market growth and these effective research and developments help in product launches for new diagnoses, and treatments to improve care for millions of people with gynecological diseases.
For instance, in July 2023, GenWorks Health launched a mechanical hysteroscopic tissue removal system that uses a simple mechanical approach for removing intrauterine tissues. It is a minimally invasive system that has been demonstrated to be quicker and can also completely remove endometrial fibroids and polyps.
Additionally, in June 2022, UroViu Corporation launched the new Hystero-V, a single-use hysteroscope compatible with UroViu's Always Ready endoscopy platform. The 12-Fr, semi-rigid, Hystero-V features a hydrophilic coating enabling gentle insertion and superior visualization for highly effective intrauterine examinations. Hence, due to the above factors, the market is expected to boost over the forecast period.
Hysteroscopy is a minimally invasive intervention that can be used to diagnose and treat many intrauterine and endocervical problems. The major investments from key companies help to drive market growth and these effective funds from national organizations and companies help to transform research discoveries into new diagnoses and treatments for gynecology diseases.
For instance, in October 2020, Meditrina raised $13 million to commercialize the Aveta system for treating intrauterine pathologies. The Aveta system is designed to use a proprietary expandable working channel hysteroscope, along with a fluid management and resection system, for hysteroscopic tissue chip resection under continuous flow conditions
Drawbacks associated with hysteroscopy include the high cost of hysteroscopy devices and procedures, lack of trained professionals in developing countries, risk of complications and infections associated with the procedure, lack of awareness and reluctance towards minimally invasive procedures in some regions, stringent regulations for approval of hysteroscopy devices and limited access to advanced healthcare facilities in rural areas. For instance, in the United States, the total cost of hysteroscopy varies between $2800 and $4800. Hence, these factors are limiting the market growth.
The global hysteroscopy market is segmented based on product, application, end users, and region.
The use of mechanical tissue removal hysteroscopy systems is more frequently implemented as the first-line approach for the treatment of intrauterine pathology. Hysteroscopic tissue removal and retrieval is a procedure performed under local or general anesthesia that allows the doctor to check inside the uterus and remove any polyps or fibroids under direct vision. Tissue removal hysteroscopy systems are expected to hold the largest market share over the period forecast owing to increasing product launches and technical advancements.
For instance, in November 2022, Medtronic plc, launched the TruClear system, a mechanical hysteroscopic tissue removal system used for the safe and effective treatment of intrauterine abnormalities (IUA). TruClear is a next-generation device that provides practitioners with a clear operative field and patients with gentle mechanical resection during the procedure to help efficiently execute a hysteroscopy.
Additionally, in February 2021, VirtaMed launched a hysteroscopy and gynecological laparoscopy mixed tissue removal platform. VirtaMed's hysteroscopy system has been updated to include 16 cases for MyoSure tissue removal, added to over 50 cases in diagnostics, polypectomy, myomectomy, and tissue ablation. Hence, the above factors help to accelerate the market growth.
The global hysteroscopy market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. North America has maintained a significant proportion of the hysteroscopy market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising prevalence and incidence of hysterectomy, and product launches in hysteroscopy devices.
For instance, according to the Centers for Disease Control and Prevention,2022, it states that hysterectomy is the second most common surgical procedure for women and approximately 600,000 hysterectomies are performed in the United States each year. Additionally, From 2012 to 2020, the age-standardized hysterectomy prevalence among adult U.S. women was 17.9%. It steadily increased with each consecutive age group and was highest among women aged more than 80 years (48.8%).
Furthermore, in December 2020, Hologic, Inc. launched its Omni hysteroscope which is an innovative three-in-one modular scope with advanced visualization capabilities designed for both diagnostic and therapeutic hysteroscopic procedures. The Omni scope, which received 510(k) clearance from the U.S. Food and Drug Administration (FDA) is designed to help physicians streamline the process of diagnosing and treating patients
The major global players in the market include: Medtronic Plc., Olympus Corporation, B. Braun Melsungen AG, Stryker Corporation, Hologic Inc., CooperSurgical Inc., XION GmbH, Richard Wolf GmbH, Karl Storz SE & Co., Delmont Imaging among others.
The COVID-19 pandemic has had a significant impact on the global hysteroscopy market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular check-ups, appointments, device launches, and consultations worldwide. Many hospitals are focused on COVID-19 cases, and this reduces the diagnosis of many patients suffering from various gynecology and obstetrics disorders.
Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the hysteroscopy market is expected to be moderately affected over the forecast period.
The global hysteroscopy market report would provide approximately 69 tables, 70 figures, and 195 Pages.
LIST NOT EXHAUSTIVE